Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

745.60 +1.10 (+0.15%)
Streaming Delayed Price Updated: 10:39 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
42 43 Next >
Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
Analyst Ratings For Regeneron Pharmaceuticals
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter: 
Via Benzinga
Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have  
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized... 
Via Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)  
Via Benzinga
Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis
The  
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Keybanc raised Take-Two Interactive Software, Inc. (NASDAQ: TTWO) price target from $185 to $190. Take-Two Interactive shares fell 2.8% to $170.21 in pre-market trading. 
Via Benzinga
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79. 
Via Investor's Business Daily
Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings
Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed. 
Via Benzinga
Stock Market Rally Volatile; Google, Facebook, Amazon, Snap Are Earnings Movers: Weekly Review
The major indexes slashed weekly gains after Monday's follow-through day. 
Via Investor's Business Daily
Regeneron Scores Quarterly Beat On Covid Cocktail — But Future Sales Are Shaky
Regeneron posted 104% sales growth, including $2.3 billion from REGEN-COV. 
Via Investor's Business Daily
Regeneron's Q4 Sales, Profits More Than Double With Boost From COVID-19 Treatment Sales
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned  
Via Benzinga
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Recap: Regeneron Pharmaceuticals Q4 Earnings
  Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q4 earnings results on Friday, February 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 4, 2022
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter. 
Via Benzinga
Earnings Preview For Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates
After a fairly robust 2021, the new year started on a mixed note as far as regulatory decisions are concerned. 
Via Benzinga
3 Biotech Stocks That Could Boom or Bust in Q1
The biotech industry is exploding. Biotech stocks provide lots of opportunities for investors who are taking a risk on the medicine's future. 
Via InvestorPlace
5 Things To Expect This Week
While the "January effect" was rather disappointing, February kicks off with an important week ahead for many types of investors. 
Via InvestorPlace
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a posi 
Via Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Promising Results Continue to Develop Optimism in Fight Against Cancers
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 27, 2021 – USA News Group – There’s plenty of optimism surrounding the major medical breakthroughs targeting multiple types... 
Via FinancialNewsMedia
A Peek Into The Markets: US Stock Futures Mostly Lower Ahead Of Earnings, Fed Meeting
Pre-open movers U.S. stock futures traded mostly lower in early pre-market trade. The Dow Jones settled higher by around 100 points on Monday after tumbling more than 1,000 points... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.